Success Metrics

Clinical Success Rate
16.7%

Based on 1 completed trials

Completion Rate
17%(1/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
5(63%)

Phase Distribution

Ph phase_2
1
13%
Ph phase_3
2
25%
Ph phase_1
5
63%

Phase Distribution

5

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

12.5%

1 of 8 finished

Non-Completion Rate

87.5%

7 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(1)
Terminated(7)

Detailed Status

Terminated5
Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
16.7%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 21 (12.5%)
Phase 32 (25.0%)

Trials by Status

withdrawn225%
completed113%
terminated563%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_3

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387
terminatedphase_3

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

NCT00662597
terminatedphase_1

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

NCT01240642
completedphase_1

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00674102
terminatedphase_1

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

NCT01278849
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00738387Phase 3

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Terminated
NCT00662597Phase 3

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Terminated
NCT01240642Phase 1

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Terminated
NCT00674102Phase 1

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT01278849Phase 1

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Terminated
NCT01299701Phase 1

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Terminated
NCT01071928Phase 2

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Withdrawn
NCT01031212Phase 1

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8